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Abstract: This study investigated if additional non-starch polysaccharide (NSP) or 
resistant starch (RS), above that currently recommended, leads to better improvement in 
insulin sensitivity (IS) than observed with modest weight loss (WL). Obese male 
volunteers (n = 14) were given an energy-maintenance (M) diet containing 27 g NSP and  
5 g RS daily for one week. They then received, in a cross-over design, energy-maintenance 
intakes of either an NSP-enriched diet (42 g NSP, 2.5 g RS) or an RS-enriched diet  
(16 g NSP, 25 g RS), each for three weeks. Finally, a high protein (30% calories) WL diet 
was provided at 8 MJ/day for three weeks. During each dietary intervention, endogenous 
glucose production (EGP) and IS were assessed. Fasting glycaemia was unaltered by diet, 
but plasma insulin and C-peptide both decreased with the WL diet (p < 0.001), as did EGP  
(−11%, p = 0.006). Homeostatis model assessment of insulin resistance improved 
following both WL (p < 0.001) and RS (p < 0.05) diets. Peripheral tissue IS improved only 
with WL (57%–83%, p < 0.005). Inclusion of additional RS or NSP above amounts 
currently recommended resulted in little or no improvement in glycaemic control, whereas 
moderate WL (approximately 3 kg fat) improved IS.  
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1. Introduction 
The increased prevalence of obesity in affluent countries has led to a rise in the associated morbidities 
of insulin resistance, with progression to type 2 diabetes, and increased cardiovascular risk [1,2]. This 
has increased pressure on primary health care costs [3] and resulted in a number of campaigns based 
on lifestyle changes to either reduce the level of obesity or at least achieve a scenario where the obesity 
has only limited impact on the co-morbidities [4–6]. The major lifestyle changes involve exercise and 
diet, especially those targeted at weight loss because even moderate reductions result in substantial 
improvements in insulin sensitivity (IS), maintenance of glycaemic control and lipaemia [7,8]. A wide 
range of approaches have been advocated to promote weight loss but there is good evidence that diets 
high in protein are particularly effective [9–11].  
For many people, however, achieving or maintaining weight loss proves difficult and so dietary 
strategies to improve metabolic health independent of weight reduction have been proposed. Such 
strategies are commonly based on lowering either the rate or amount of glucose absorbed from  
a meal [12]. This may involve substitution of some of the easily digested carbohydrate with 
fermentable sources, often grouped under the term “fibre”, that are either partially or completely 
degraded in the large intestine to short chain fatty acids (SCFA). Absorbed SCFA may also have direct 
effects on mechanisms linked to IS, either by substitution of gluconeogenic demands or by enhancing 
glucose uptake by muscle and adipose tissue [13]. Soluble forms of fibre also slow the rate of glucose 
absorption from the small intestine and thus lower glycaemic excursion in the post-prandial state [14]. 
Structurally, fibre can be sub-divided broadly into two forms, resistant starch (RS) and non-starch 
polysaccharide (NSP). While both can be fermented in the colon, the exact site, rate of degradation and 
the nature of the SCFA released can vary [15] and these may affect IS and other metabolic parameters, 
either directly or indirectly. Indeed, a number of studies have reported that inclusion of fibre within the 
meal strategy [16] or use of either acute [17] or chronic [18] supplementation with RS does improve 
blood glucose control following a meal. It is less clear whether NSP is as effective as RS, however, 
and this is important because the former is the more prevalent form of fibre in Western diets. 
Furthermore, it is not known whether improvements in metabolic health associated with higher fibre 
intake at weight maintenance match those achieved with a modest reduction in body weight. These two 
questions were addressed in the current study. In view of the important contribution of amino acids as 
glucose precursors [19–22], a secondary aim was to assess the impact of the various dietary 
interventions on protein turnover and amino acid status. Additional questions linked to aspects of 
colonic health, as assessed by changes in the microbial populations [23] and enzyme activities [24] of 
stool samples were also addressed within the overall study but have been reported separately. 
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2. Experimental Section 
This study was conducted according to the guidelines laid down in the Declaration of Helsinki and 
all procedures were approved by the North of Scotland Research Ethics Service (reference code 
07/S0802/35, May 2007). Written consent was obtained from all participants. Subject information, 
nutrient intakes and fibre digestibility have been detailed elsewhere [23,24]. Briefly, 16 male 
volunteers were recruited, each with at least three symptoms of metabolic syndrome (including waist 
circumference > 102 cm, body mass index > 27 kg/m
2
 and fasting glucose > 6 mM). Two left the study 
for reasons unconnected with the protocol. The remainder (n = 14) completed 4 periods of dietary 
intervention, with all food supplied in cooked or ready-to-eat form. The volunteers were first provided 
for 7 day with a maintenance (M) diet of breakfast, lunch and dinner based on a 3-day rotating menu. 
The estimated metabolisable energy (ME) intake for this diet was based on 1.5× resting metabolic rate 
(measured in the overnight fasted state) for each individual and provided protein:carbohydrate:fat as 
13:52:35 of calories. For the M diet, the RS and NSP intakes averaged 5.1 and 27.1 g/day [23]; the 
latter exceeds the current UK recommendations (18 g/day) but is similar to that proposed for men in 
other Northern European countries [25]. The second and third periods each lasted for 21 day and 
involved either the RS or the NSP diet, offered in a randomised order. With the additional NSP or RS 
given these two diets provided approximately double the recommended daily dietary fibre intake in the 
UK. Both diets provided the same ME intake and similar macronutrient composition as for the  
M period. The RS diet contained 60 g/day of Novelose 330 (type 3 resistant starch), such that average 
daily intake of RS was 25.4 g/day while the measured NSP intake was 16.0 g/day (but only 8 g/day 
from food tables used to devise the menus). The NSP diet contained additional bran and other 
structural carbohydrates and provided, on average, 41 g NSP per d while the RS intake was 2.5 g/day. 
Both the RS and NSP diets were provided on a 5-day rotation menu. The final period was a 21-day 
weight loss (WL) based on a high-protein strategy [26] with the total ME intake as 8.5 MJ/day for all 
volunteers and with 30:40:30 for the energy content as protein, carbohydrate and fat respectively, 
while NSP and RS were set at 25.1 and 2.9 g/day respectively. There was no washout period  
between any of the dietary periods and any food refusals were recorded daily. The ratio of 
soluble:insoluble NSP was calculated from composition tables to be approximately 1:6 for the NSP 
diet and 1:3 for the others, but subsequent chemical analysis of the diets yielded ratios from 1:3.8 to 
1:7.6. At the end of each period body weight and fat content was measured by air-displacement 
plethysmography as described previously [11]. Stool samples were collected weekly and analyses of 
these for undigested fibre content and microbial populations have been reported elsewhere [23]. 
2.1. Kinetic Measurements 
Endogenous glucose production (EGP) was quantified by [6,6-
2
H2]glucose infusions and this, in 
combination with infusion of [U-
13
C]glucose and measurement of plasma insulin, also allowed IS to be 
determined, based on adaptation of established Minimal Models. Protein turnover in the fasted state 
was estimated using [1-
13
C]leucine. All isotopes were obtained from Cambridge Isotope Laboratories 
(CK Gas Products, Hook, Hants, UK) and were of either metabolic grade or tested for sterility and 
pyrogenicity. On the last day of each dietary period the volunteers were fasted overnight (last meal 
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before 2100 on the previous day) and attended the Human Nutrition Unit at 07:00. The volunteers 
voided before the following procedures. An 18 g Venflon cannula with a 3-way tap added was inserted 
in an antecubital vein and used for infusions. Another Venflon cannula (20 g) was inserted into a vein 
on the back of the contralateral hand in a retrograde direction and was used for “arterialized” blood 
sampling using a hot box set at 60 °C. With some volunteers it proved difficult to catheterise the hand 
vein and in these cases the sample catheter was inserted into an antecubital vein in the contralateral 
arm. Unless otherwise specified, all blood samples were taken into heparinised Monovette tubes 
(Sarstedt Ltd, Leicester, UK). A 9 mL sample was taken for overnight-fasted metabolic parameters and 
for determination of natural abundance for subsequent stable isotope procedures. Unless otherwise 
stated all subsequent blood samples were collected into heparinised tubes. 
The protocol for the subsequent metabolic procedures is detailed in Figure 1. The design included a 
2 h pre-measurement (−120 to 0 min) of endogenous glucose production and whole body protein 
breakdown under fasting conditions, then a 2 h measurement (0 to 120 min) of glucose rate of 
appearance (Ra) during a continuous intravenous infusion of glucose (37.5 g/h) followed by  
a 2h recovery period (120–240 min). Throughout the whole 6 h a 500 mL solution of [6,6-2H2]glucose 
(containing 160 µmol/kg BW; infusion rate 0.4 µmol/kg body weight (BW) per min) in sterile solution 
was infused (75 mL/h). At the start of the fasted measurements (time—120 min), the volunteers were 
given a weighed priming injection of [6,6-
2
H2]glucose (42 µmol/kg BW) plus [1-
13
C]leucine  
(4.2 µmol/kg BW) dissolved in 10 mL sterile saline and for the first 2h [1-
13
C]leucine  
(9.6 µmol/kg BW; infusion rate 0.08 µmol/kg BW per min) was included with the [6,6-
2
H2]glucose 
infusate. Arterialised blood samples (5 mL, plus 1 mL into EDTA) were taken at −60, −50, −40, −30, 
−20, −10 and −1 min with the subjects asked to place their hand in a hot box at 60 °C for the 5 min 
before each sample was taken. For the next 2 h (0 to 120 min) a 50% dextrose solution (2.78 M; Baxter 
Healthcare, Newbury, Berks, UK) containing [U-
13
C]glucose (6.45 mM; infusion rate 0.008 µmol/min) 
was infused (75 mL/h) through another port of the 3-way tap. Blood samples (2 mL, plus 1 mL into 
EDTA) were then taken at 5, 10, 15, 20, 30, 40, 50 59, 62, 64, 66, 68, 70, 75, 80, 90, 100, 110 and  
120 min. At 60 min insulin (0.6 IU/mL, prepared by diluting 100 IU/mL Actapid with diluting 
medium, both from Novo Nordisk, Crawley, Sussex, UK) was injected at 0.04 IU/kg BW via the 
antecubital vein cannula and flushed through with 20 mL sterile saline. At 120 min the dextrose 
infusion was discontinued and blood samples (2 mL, plus 1 mL by syringe into EDTA) taken at 125, 
130, 135, 140, 150, 160, 170, 180, 210, 240 min. At the end of the infusions the subjects emptied their 
bladder and the collected urine was weighed and 10 mL retained. Volunteers were allowed access to 
water during the infusion period. At the end of each infusion the pumps and tubing were calibrated 
gravimetrically and these values used to calculate actual rates of infusion. 
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Figure 1. Time line (min) of the various infusions on the last day of each dietary period. 
The vertical dashes on the time line indicate sampling points. The [1-
13
C]leucine and  
[6,6-
2
H2]glucose were infused at tracer amounts, while the dextrose infusion represents  
a 75 g glucose challenge infused over 2 h. Insulin was injected at 0.04 IU/kg body weight 
(BW) at 60 min after start of dextrose infusion. 
 
On one separate occasion for each volunteer, after an overnight fast a bolus injection of  
[U-
13
C]glucose (12 µmol/kg) was given via a cannula inserted into an antecubital vein and blood 
samples (2 mL) taken from the same cannula at −5, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 
18, 20, 22, 24, 26, 28, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 105, 120, 135, 150 min. The bolus 
injection was randomised between volunteers to encompass all the dietary treatments.  
2.2. Laboratory Analyses 
All blood samples were immediately placed on ice and centrifuged at 1000× g for 15 min at 4 °C. 
Samples were either stored at −80 °C for later analyses or used fresh for immediate measurement of 
glucose concentration with a clinical analyser (Kone Ltd., Espoo, Finland) based on the hexokinase 
reaction (Thermo Fisher Ltd., Vantaa, Finland). Each sample measured in quadruplicate and care taken 
to prevent evaporation while the tubes were contained within the thermostatically-controlled well. For 
the bolus injection, glucose concentrations were determined on the samples taken at −5, 120, 135 and 
150 min and the mean value used for the compartmental analysis. 
All enrichments of [6,6-
2
H2] and [U-
13
C]glucose were determined as the penta-acetate derivatives 
and data expressed as tracer:tracee ratio (TTR), corrected for appropriate background. To ensure 
uniform peak areas, volumes of plasma (to the nearest 5 µL) were processed to yield 0.25 µmol 
glucose, based on the clinical analyser data. Plasma (20 to 70 µL) was added to 200 µL 
acetonitrile:ethanol mixture (2:1), vortex mixed for 30 s then centrifuged at 12,000× g for 5 min. The 
supernatant was dried at 90 °C under nitrogen. To the dry residue was added 75 µL acetic 
anhydride:pyridine (2:1) and the penta-acetate derivative formed by heating at 90 °C for 15 min, 
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followed by drying and dissolution in 80 µL ethyl acetate. The [6,6-
2
H2]glucose was analysed on  
a Voyager mass spectrometer (Thermo Scientific, Hemel Hempstead, UK) coupled to a GC8000 Top 
gas chromatograph, with a 30 m × 0.25 mm × 0.25 µm Equity-1701 capillary column (Sigma-Aldrich, 
Gillingham, UK). The [6,6-
2
H2]glucose was measured under electron impact conditions with selective 
ion monitoring of fragment ions at m/z 200 and 202. The [U-
13
C]glucose (bolus injection) was 
determined under positive chemical ionization gas conditions on an Agilent 5973 Network MSD 
(Agilent Technologies, Manchester, UK) coupled to a 6890N gas chromatograph, with an Equity-1701 
capillary column. Methane was used as the reagent gas and the ions at m/z 331 and 337 were 
monitored under selective ion monitoring conditions.  
Enrichments of [U-
13
C] glucose (from dextrose infusion) were determined by gas chromatograph 
combustion isotope ratio mass spectrometry (Delta plus XL fitted with a GC C II-III interface; Thermo 
Scientific, Winsford, Cheshire, UK). All penta-acetate derivatives were made to 400 µL with  
ethyl acetate and 1 µL injected in splitless mode onto a DB1701 column (30 m i.d., 0.322 film,  
0.25 µM). All samples were measured in duplicate but if the standard deviation exceeded  
0.001 atom % excess the analyses were repeated in duplicate. Background enrichments were based on 
the average of samples taken −20, −10 and 0 min before the start of the dextrose infusion (i.e., during 
the [6,6-
2
H2]glucose plus [1-
13
C]leucine infusion). Urine was analysed where there were detectable 
amounts of glucose present (>0.2 mM). Enrichment of each infusate was also measured and  
averaged 99% (SE 0.7%) of those calculated from the weight of [U-
13
C]glucose added to the  
50% dextrose solution. 
The TTR for both leucine and its oxo-acid, 4-methyl-2-oxo-pentanoate (MOP), were determined 
from 0.9 mL plasma as previously described [27]. Amino acid concentrations were determined by 
isotope dilution with a gravimetric approach (to give µMolal) as described previously [28], but with 
two additions, homocysteine [29] and arginine, the latter was monitored at m/z 442 and 448 as a nitrile 
breakdown product of the derivative that eluted between lysine and histidine [30].  
Plasma insulin and C-peptide concentrations were measured in duplicate by ELISA kits (Mercodia, 
Uppsala, Sweden). Insulin was measured on all samples for all diets. C-peptide was measured only for 
the M and WL treatments and was restricted to samples taken at 10 and 0 min before the start of the 
dextrose infusion and then at 10, 20, 30, 40, 50, 59, 75, 90, 100, 110, 120, 130, 140, 150, 160, 170, 
180, 210, 240 min. Any duplicate samples with a CV greater than 10% were re-analysed. The 
coefficient of variation for intra- and inter- plate assays were 5.8% and 7.2% for insulin and 4.8% and 
3.7% for C-peptide respectively. The factor 6.0 was used to convert insulin from mU/L to pM,  
where appropriate. 
2.3. Calculations 
The Homeostatic Model Assessment of insulin resistance (HOMA2-IR) [31] was calculated using a 
freely-available programme [32] based on the mean of the 7 fasted samples taken at 10 min intervals 
during the last hour of the [6,6-
2
H2]glucose plus [1-
13
C]leucine infusion. The sample taken 5 min after 
the bolus “prime” injection showed elevated glucose and insulin and was not used. Hepatic insulin 
sensitivity (HIS) [33] was calculated as 1000/(EGP × fasting plasma insulin). 
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Both incremental (AUCi) and total (AUCt) areas under the curve for glucose, insulin and C-peptide 
were calculated by the trapezoid method [34]. For comparisons between metabolites and hormones 
only identical samples were used, i.e., for glucose and insulin all samples for all treatments were 
examined, while for insulin versus C-peptide the analysis was restricted to the sample times selected 
for C-peptide and for only M and WL diets. 
The irreversible loss rates (ILR) of leucine, using plasma MOP as precursor, and EGP for glucose 
under fasting conditions were based on the 7 samples obtained during the hour preceding the dextrose 
infusion and for which a pseudo-plateau was reached. ILR (mmol/h) was calculated from 
ILR (mmol/h) = 
     i   rate    la elled eta  lite     l    
    eta  lite i   la  a
  
2.4. Insulin Sensitivity 
2.4.1. Rationale 
For this study, a Minimal Model approach to measure IS was adopted. This has the advantage over 
the hyperinsulinaemic, euglycaemic clamp (HIEC) in that elements of pancreatic function and hepatic 
responsiveness could also be obtained. The IV rather than oral method was preferred because the 
former allows accurate definition of entry of glucose into the plasma, while the latter requires 
estimation of the rate of absorption of the glucose and necessitates another (and radioactive) tracer [35] 
in addition to the conventional 
13
C and 
2
H glucose tracers [36]. A model based on infusion rather than 
the conventional bolus injection [37] was developed to allow a greater amount of glucose to be 
supplied (75 g over the 2 h compared with the conventional intravenous bolus dose of 20 g) and that 
matches with the amount normally given as part of an oral glucose tolerance test for determination of 
impaired glucose tolerance or type 2 diabetes. Two models (Formal and Simple) were constructed to 
predict IS.  
Although the dextrose challenge was supplied at a constant rate, both the initial response to the 
infusion and the return to baseline conditions when the infusion was stopped are under non-steady state 
conditions. For this reason, estimates of the main parameters of the compartmental model shown in 
Figure 2 were needed. These parameters were then used for the fits to the equations derived for the 
Formal and Simple Models. 
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Figure 2. Three compartment model to describe transfers from a primary pool (A) to either 
a readily accessible (B) or less-readily accessible (C) pool. Values obtained from  
14 volunteers with each measured on just one occasion in the overnight fasted state. 
Subjects were injected intravenously with a bolus dose of [U-
13
C]glucose and blood 
samples taken at intervals over 150 min. A three compartment model was fitted to the TTR 
of plasma glucose. Values in parentheses include all volunteers, other values exclude two 
volunteers for whom inadequate model fits were obtained. Values beside arrows are 
fractional rate constants (min
−1
). 
 
2.4.2. Estimation of Compartmental Model Parameters from Bolus Dose [U-
13
C]glucose  
The [U-
13
C]glucose enrichments were expressed as TTR. Due to imperfect mixing within the body, 
samples collected within 90 s of dosing were excluded. Fitting a 3-pool model to the enrichments gave 
the best fit (comparison of residual sum of squares using the F-test, p < 0.001): 
TTR =     
           
           
       
where t is the sampling time (min), and A1, h1, A2, h2, A3 and h3 are the parameters to be estimated.  
For 12 volunteers the accounted variance, adjusted for the degrees of freedom, exceeded 99.5%, while 
for the other two volunteers the accounted variance was 88.3% and 94.0%. The estimates of A1, h1, A2, 
h2, A3 and h3 were transformed into pool sizes and fractional rate constants by conventional  
procedures [38]. The notation used is as follows. Qx (mmol) refers to the size of pool x, and kx (min
−1
) 
denotes the fractional rate constant for this pool. Furthermore, kyx is defined as the fractional rate 
constant such that flows to pool y from pool x are given as kyx × Qx. The following assumptions [39] 
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were made (see also Figure 2): EGP enters the system via the primary pool (pool A) that then 
exchanges glucose with pool B (rapid equilibration) and pool C (slow equilibration) but there is no 
exchange between these latter two pools. Finally, loss from the system occurs from pools B and C, 
where two scenarios were considered; the first assumes that 75% of the loss occurs from pool B and 25% 
from pool C [39], whereas the second assumes that 100% of the loss occurs from pool B. 
2.4.3. Adapting the 3-Pool Model Parameters to a 2-Pool Model 
For estimation of EGP and ILR on experimental days a simpler model was used [34,40], based on  
2 pools with EGP entering and ILR leaving the primary pool, and with the secondary pool acting as the 
peripheral compartment. To distinguish this model from the 3-pool model, the primary and secondary 
pools are referred to as pool 1 and pool 2, respectively. The volume (V, L) of the primary pool for each 
of the four experimental days was obtained from the amount of prime dose divided by the  
[6,6-
2
H2]glucose concentration in plasma measured 5 min after the dose was injected. For each 
volunteer the estimated volume was similar for each of the four diets and so the average was used. 
Finally, for each experimental day the pool sizes and rate constants of the 2-pool model were adjusted 
such that the ILR from the 2-pool model matched the ILR obtained from the continuous infusion of 
[6,6-
2
H2]glucose during baseline. In conjunction with V and the baseline glucose concentration, the 
pool size of the primary pool and k01 (min
−1
) were determined. Assuming k2 and k01/k1 are unchanged, 
then the remaining parameters were obtained. This approach resulted in parameters specific to each 
diet for each volunteer. On average, k01 = 0.0111/min (SEM 0.0003), k21 = 0.026/min (SEM 0.003),  
k12 = 0.034/min (SEM 0.002), V = 15.3 L (SEM 0.28; or 0.128 L/kg body weight), Q1 = 92.8 mmol 
(SEM 4.3), and Q2 = 74.7 mmol (SEM 8.3).  
2.4.4. Concentrations of Various Glucose Species 
For each experimental day, the measured total glucose concentration in plasma, denoted by Gtot,  
is a composite of [6,6-
2
H2]glucose, [U-
13
C]glucose and natural abundance glucose, with the latter 
comprising glucose derived from endogenous sources plus that present in the dextrose infusate. Values 
for each glucose form were obtained from the enrichment (TTR) data.  
2.4.5. Formal Model for Estimation of ILR and EGP during Dextrose Challenge 
The two-compartmental model structures and assumptions detailed elsewhere [35,40,41] were taken 
as the starting point. Differences were that ILR was assumed to occur solely from the primary pool 
and, because several volunteers of this “at risk” population showed an increase in the GD2 
concentration during the first 30 to 60 min of the dextrose challenge, allowance was made for 
inhibition of fractional removal rate at high glucose concentrations. This was modelled as follows: let 
ILR denote the irreversible loss rate of all glucose species (mmol/min) combined, and assume that 
ILR(t) = k01(t)·Gtot(t)·V  
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where k01(t) is modelled as  
           
       
   
      
         (1) 
with    
  (min
–1
) the fractional removal rate constant at baseline. It is also assumed that 
    
  
   
     
 
                   
      
 
                (2) 
  
  
  
                          (3) 
where QD2 denotes the pool size (mmol) of the secondary pool for the [6,6-
2
H2]glucose and InfD2 is the 
infusion rate (mmol/min) of the [6,6-
2
H2]glucose. Furthermore, 
  
  
      
 
              
     (4) 
  
  
      
 
        
 
    
     (5) 
where     
     = Gtot(t) − Gtot(0), if Gtot(t) > Gtot(0); and     
     = 0, for Gtot(t) ≤ Gtot(0). Ins
+
 were 
defined similarly. The use of z(t) in Equation (1) acts as inhibition on the fractional removal rate 
constant k01 under excess glucose load, where it is assumed that the maximum inhibition is limited to 
k01 being reduced by half. The rate of inhibition is modelled by means of parameter g1 (L/mmol/min) 
in Equation (5). The use of x(t) in equation (1) acts as enhancer of glucose removal due to high insulin 
concentrations, where the enhancement rate is modelled by means of sk (L/mU/min
2
) in Equation (4). 
This equation shows that for high insulin concentrations x(t) will be large and hence ILR will be 
enhanced. The parameters px (min
−1
) and pz (min
−1
) model the gradual decay of the enhanced (or 
suppressed) removal with time. 
Qend(t0) was set equal to Q2 from the adapted 2-pool model and QD2(t0) was set equal to Qend(t0) 
GD2(t0)/Gend(t0), where the start time t0 was taken to be 30 min prior to the start of the dextrose 
infusion. Furthermore, x(t0)=0 and z(t0)=0. Using R (R Foundation for Statistical Computing, Vienna, 
Austria, [42]), in conjunction with the gnlm (by Lindsey, J., [43]) and odesolve (CRAN repository  
on [42]) libraries, parameter estimates were obtained from minimising the weighted residual sum of 
squares, with weights given by the length of the interval between time points. The latter avoided the fit 
being dominated by samples taken close together. The percentage of variation accounted exceeded 
80% for 48 of the 56 data sets. This was less for the remaining data, either due to variable GD2 
concentrations throughout the time course of the study or due to the model failing to capture the rapid 
fluctuations observed in GD2 following the insulin bolus. 
2.4.6. Simple Model for Estimation of ILR and EGP during Dextrose Challenge 
A simpler model, requiring fewer assumptions, has also been developed [35] but this involved use 
of a third (and radioactive) tracer which could not be adopted in the current study. Therefore the ILR 
and EGP calculations [35] were adapted for 2 tracers based on the observed changes in GD2 and Gend. 
Again, the 2-pool model with ILR and EGP occurring from the primary pool was taken as starting 
point, where it was assumed that k12, k21 and V remain unchanged, but that ILR (and hence k01) and 
EGP vary with time. In steady state, ILR (covering losses of all glucose species) is given as  
Nutrients 2013, 5 2154 
 
 
ILR = k01 × Gtot × V and EGP will be equal to ILR. During the dextrose challenge, however, ILR is 
expected to increase and EGP to decrease. The ILR at time point t is modelled as 
ILR(t) = k01(t) × Gtot(t) × V (6) 
which allows for a variable fractional rate constant (for example, ILR may increase more rapidly than 
predicted from ILR(t) =    
 ·Gtot(t)). The changes in the GD2 concentration and pool size are modelled 
as described in Equations (2) and (3). 
For δ sufficiently small, dQD2/dt can be written as [QD2(t + δ) − QD2(t))/δ], so that from Equation (3) 
QD2 is obtained: 
QD2(t + δ) = QD2(t) + δ × [k21 × GD2(t) × V − k12 × QD2(t) ] 
where GD2(t) is based on the observed [6,6-
2
H2]glucose concentration. Likewise, writing dGD2/dt = 
(GD2(t + δ) − GD2(t))/δ, k01(t) follows from equation (2): 
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ILR(t) can now be calculated from Equation (6). To obtain EGP(t), the changes in the  
Gend concentrations are modelled as: 
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Analogous to QD2, by writing dQend/dt = (Qend(t + δ) − Qend(t))/δ and dGend/dt = (Gend(t + δ) − 
Gend(t))/δ, Qend is obtained from Equation (8): 
Qend(t + δ) = Qend(t) + δ [k21 × Gend(t) × V − k12 × Qend(t)]   
so that, from Equation (7): 
        
 e d    δ    e d   
δ
       e d        
 
e d
   
 
         e d         
Qend(t0) was set equal to Q2 from the adapted 2-pool model and QD2(t0) was set equal to  
Qend(t0) × GD2(t0)/Gend(t0), where the start time t0 was taken to be 60 min prior to the start of the 
dextrose infusion.  
Implementation of the above was based on smoothed data (using the smooth.spline function in R on 
20 degrees of freedom (df)) with concentrations estimated at every 0.01 min (so that δ = 0.01 min), so 
that estimates of ILR, EGP and k01 were obtained for every 0.01 min. Any negative outcomes were set 
equal to zero and all results were lightly smoothed (20 df). The detailed ILR, EGP and k01 were 
summarised by averaging over 60 min intervals. 
Constraints by the local Ethics Committee on the amount of bolus insulin injected meant that only 
small perturbations in kinetic responses occurred and thus the action of insulin could not be separated 
from those of insulin plus glucose in the current experiment. 
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2.5. Statistical Analysis 
Data are only considered for those volunteers (n = 14) who completed all four periods of the study. 
The design fixed the order of the maintenance and weight loss diets (periods 1 and 4 respectively) and 
only the order of the RS and NSP diets were randomised (across periods 2 and 3). For these  
two high-fibre diets a cross-check was performed that just compared these two diets with volunteer and 
period within volunteer as a random effect and period and diet, plus their interaction, as fixed effects. 
For all comparisons period was not significant so data from all four diets were analysed by Analysis of 
Variance (ANOVA), using Genstat 13th Edition Release 13.1 (VSN International Ltd., Hemel 
Hempstead, Herts, UK), with period effects ignored. For comparisons between diets, volunteer was 
treated as a random effect with diet as a fixed effect. For one volunteer, no [U-
13
C]glucose was 
included in the dextrose infusion during the M diet, and this was treated as a missing value  
where appropriate.  
The stability of the plateaux for the leucine kinetics and endogenous glucose production (EGP) 
under fasting conditions on each experimental day (i.e., several sample times for each period for  
each volunteer) were tested by ANOVA with volunteer, and with period, sample time and their 
interaction nested within volunteer, as random effects and with diet and sample time, plus their 
interaction, as fixed effects. 
Outcomes from the Simple model were aggregated over each of the four 60 min intervals for each 
volunteer period and analysed by ANOVA with volunteer, and with period, interval and their 
interaction nested within volunteer, as random effects, and with diet and interval, plus their interaction, 
as fixed effects.  
For all analyses, where significant main effects were observed (p < 0.05, all tests 2-sided) then 
difference between treatments were analysed by post-hoc t-test based on the relevant standard error of 
difference (SED), although only the SED for effect of diet are presented in the tables. Where reported 
in the text, the standard error of the mean (SEM) includes variation both within- and  
between-volunteers. 
3. Results 
3.1. Fasted Parameters (Table 1)  
For the first 3 dietary interventions both mean body weight (121.1 kg) and body fat (49.0 kg) were 
similar, but declined by 6.1 kg and 4.9 kg (both p < 0.001) respectively following WL. 
There was no effect of diet on plasma glucose concentration but, following the WL diet, insulin 
decreased by 35% (p < 0.001). In consequence, the HOMA2-IR also decreased with the WL diet  
 − 7%, p < 0.001). A reduction in HOMA2-   wa  al      erved a ter t e  S diet  − 4%, p < 0.05 
compared with the M and NSP diets). Similarly, β-cell function (HOMA2-%B) and IS (HOMA2-%S) 
both improved under WL compared with the other 3 diets. C-peptide was also 28% lower following 
WL (p < 0.001, compared with the M diet). The ratio of C-peptide:insulin, with both expressed as pM, 
increased between the M and WL diets (17.5 vs. 21.8, SED 1.76, p = 0.031). 
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Table 1. Effect of diet and time of sampling on various parameters 
1
 after an overnight fast 
following consumption of either a 7-day maintenance (M), or 21-day high non-starch 
polysaccharide (NSP), high resistant starch (RS) or weight loss (WL) diets by obese men 
(n = 14). 
Parameter M NSP RS WL SED 
P 
4
 
Diet 
P 
5
 
Time 
Glucose mM 6.13 6.01 5.91 6.03 0.127 0.392 0.011 
Insulin pM 94.9 a 95.0 a 81.8 a 59.4 b 1.109 <0.001 0.214 
C-peptide pM 1505 ND ND 1085 83.1 <0.001  
EGP μmol/min 2 1041 a 995 a 996 a 923 b 30.6 0.006 <0.001 
EGP μmol/min/kg FFM 3 15.13 a 14.56 a,b 14.65 a 13.72 b 0.444 0.027 <0.001 
HOMA2-IR 1.83 a 1.83 a 1.58 a 1.16 b 0.129 <0.001  
HOMA2-%B 93.2 a 96.0 a 90.7 a 69.1 b 5.15 <0.001  
HOMA2-%S 71.9 a 80.6 a 80.3 a 130.1 b 14.07 <0.001  
HIS 14.2 a 15.9 a 16.2 a 28.3 b 3.12 <0.001  
1 Mean values for glucose, and insulin based on 7 samples taken during 60 min prior to the dextrose infusion. 
C-peptide (only measured for M and WL diets and based on mean of samples taken at −10 and 0 min before 
start of dextrose infusion. ND, not determined). HOMA2, various Homeostatic model assessments (2) for IR, 
insulin resistance; %B, % pancreatic function; and %S, % insulin sensitivity [32]. HIS Hepatic Insulin 
Sensitivity (106/(EGP × fasting plasma Insulin) [33]; 2 EGP endogenous glucose production; 3 FFM, fat-free 
mass; 4 For effect of diet based on ANOVA with volunteer as random effect, and with diet as fixed effects  
39 residual degrees of freedom (df). SED values are presented for the effect of diet and differences between 
diets are represented by unlike superscripts within rows (p < 0.05); 5 For effect of time within sample day  
(for 7 samples taken between 60 and 120 min from start of infusion) by ANOVA, with random effects for 
volunteer and nested within volunteer, period, time and their interaction. Diet, time and their interaction were 
regarded as fixed effects; 78 residual degrees of freedom for testing the effect of time. 
3.2. Basal Glucose and Leucine Metabolism 
During the last hour of the fasted period, the plasma glucose concentration decreased by 2.2%  
(p < 0.001) across all diets. The altered glucose concentration, and thus pool size, may account partly 
for the slight increase (+8%; p <0.001) in [
2
H2]glucose TTR over the same time interval, although this 
may also involve return of label from intermediate pools [38]. EGP, expressed either in absolute units 
(p = 0.006) or corrected for fat free mass (FFM; p = 0.027), was lower with the 3 weeks of WL  
(Table 1) although, in the latter case, this was not significantly different from the NSP diet. For the  
WL diet the combination of lowered EGP and fasting insulin led to a higher estimated HIS (Table 1).  
During the last 60 min of [1-
13
C]leucine infusion the TTR increased for both Leu (+2.8%) and MOP 
(+2.2%) but the ratio of MOP:Leu enrichments was unaltered (data not shown).  
Diet had no effect on any of these responses. In terms of whole body kinetics (Table 2) diet also had 
no effect on ILR (equivalent to protein breakdown when intake is zero) based on plasma leucine 
enrichment (data not shown). The ILR (protein breakdown) based on plasma MOP did differ between 
diets, however, with lower values for NSP (p < 0.05) and WL (p < 0.001) compared with the M and 
RS diets (Table 2). These differences in ILRMOP between treatments occurred despite similar overnight 
fasted plasma Leu concentrations and those of the other branch chain amino acids (Table 2). In 
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contrast fasting plasma concentration of Trp was decreased (p < 0.01) on the WL diet as were Ala, Glu 
and Tyr, while Ser increased (p < 0.001). In addition, the concentration of Pro was lower (p < 0.01) 
with the RS compared with the NSP diet.  
Table 2. Overnight fasted irreversible loss rate (ILR; based on plasma MOP 
1
) and plasma 
amino acid concentrations (µMolal) at the end of each dietary intervention period 
2
 for  
14 volunteers.  
AA 
3
 Maint NSP RS WL SED P 
4
 Diet 
ILRmop 
μmol/min 
200.6 a 188.3 b 198.0 a 177.2 c 4.91 <0.001 
Ala μmol/kg 404.3 a 382.5 a,b 362.8 b 299.1 c 16.31 <0.001 
Arg μmol/kg 101.9 a 97.5 a,b 94.7 b,c 89.1 c 3.53 0.007 
Asp μmol/kg 4.0 3.7 3.4 3.0 0.40 0.076 
Cys μmol/kg 300.1 a 302.1 a 287.9 a,b 298.3 a 3.63 0.002 
Gln μmol/kg 587.4 593.5 578.8 566.3 13.70 0.233 
Glu μmol/kg 98.0 a 93.6 a 90.1 a 70.8 b 5.73 <0.001 
Gly μmol/kg 169.6 174.7 164.3 162.8 5.85 0.176 
Hcy μmol/kg 6.7 a 6.4 a,b 6.1 b 6.5 a 0.19 0.017 
His μmol/kg 79.5 a 77.3 a,b 75.4 b,c 72.4 c 1.64 <0.001 
Ile μmol/kg 73.4 78.0 75.6 74.5 3.06 0.485 
Leu μmol/kg 146.6 141.3 140.3 137.9 4.44 0.258 
Lys μmol/kg 180.6 176.9 177.1 179.9 4.99 0.833 
Met μmol/kg 29.1 a 27.1 b 25.9 b,c 24.3 c 0.87 <0.001 
Phe μmol/kg 65.9 a 61.1 b 62.4 b 59.5 b 1.44 <0.001 
Pro μmol/kg 229.3a 203.6a 179b 171.5b 7.83 <0.001 
Ser μmol/kg 85.7 a 85.1 a 82.7 a 94.1 b 2.36 <0.001 
Thr μmol/kg 117.4 114.6 117.2 119.5 5.19 0.829 
Trp μmol/kg 58.6 a 58.9 a 59.9 a 54.0 b 1.50 0.001 
Tyr μmol/kg 85.2 a 78.7 b 77.8 b 72.0 c 2.54 <0.001 
Val μmol/kg 248.2 242.3 244.1 253.7 6.61 0.336 
1 MOP, 4-methyl-2-oxopentanoate (oxo-acid of leucine); 2 7 day maintenance (M), or 21 day high non-starch 
polysaccharide (NSP), high resistant starch (RS) or weight loss (WL) diets; 3 Ala (alanine), Arg (arginine), 
Asp (aspartic acid), Cys (cysteine + cystine), Gln (glutamine), Glu (glutamic acid), Gly (glycine), Hcy 
(homocysteine), His (histidine), Ile (isoleucine), Leu (leucine), Lys (lysine), Met (methionine), Phe 
(phenylalanine), Pro (proline), Ser (serine), Thr (threonine), Trp (tryptophan) Tyr (tyrosine), Val (valine);  
4 p-value for Diet obtained from ANOVA, with subject as random effect and diet as fixed effect, 39 residual 
d.f. Data in rows with unlike superscripts differ by p < 0.05. Comparison of NSP v RS was also conducted by 
2-way ANOVA with volunteer as random effect and diet and period, and their interaction, as fixed effects,  
12 residual d.f. This is the only part of the design that was randomised cross-over and there were no 
significant effects of period (order). 
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3.3. Bolus [
13
C]Glucose Injections 
Data for the 3-compartment model [39] fitted to the plasma enrichment curves following an 
intravenous injection of [
13
C]glucose for each volunteer in the overnight fasted state are shown in 
Figure 2. For two volunteers the 3-model fit gave small estimated primary pools, possibly due to 
incomplete mixing at the site of injection. For the other volunteers, the outflow from pool A to the 
rapid-equilibration pool (kba) varied from 0.143 to 0.589 per min compared with 0.030 to 0.0.201 per 
min for the slow-equilibration pool (kca). Such variation required that individual parameters were fitted 
for each subject. Overall the mean values for kca were similar to those observed for young, lean 
subjects (0.047/min) while kba was much lower than the 1.09/min reported previously [39]. The kba has 
been associated with insulin-independent transfers of glucose and the lower values may reflect 
inhibited uptake in the current obese subjects. The half-life of pool B ranged from 2 to 7 min (average 
2.9 min) while that of pool C varied from 12 to 99 min (average 20 min). This means, on average, 
that >1 h would be needed to achieve a new equilibrium in the transition between steady states and that 
under non-steady state conditions, as in the current study, transfers from pools B and C would impact 
on measurements in pool A, which includes the sampled plasma. 
The 3-compartment model parameters were simplified to those of a 2-compartment model by 
merging the first two pools and assuming that both EGP and ILR occur from the primary pool [35,40]. 
This formed the basis for subsequent estimation of EGP and ILR during the dextrose challenge. One 
outcome was that the model parameters for the two subjects that had a small estimated primary pool 
based on the 3-compartment model were now within the range observed for the other volunteers. For 
this reason the 2-compartment model was considered more robust. The fractional rate constants 
between pools 1 and 2 averaged k21 = 0.026 (SEM 0.003) per min and k12 = 0.034 (SEM 0.002) per 
min and these are lower than those reported for lean subjects (0.05 and 0.07 per min, respectively) [35]. 
3.4. Responses to Dextrose and Post-Dextrose Recovery 
Mean concentrations for plasma glucose and insulin for each hour both during and following the 
dextrose infusion across diets are given in Table 3. 
Although the amount of dextrose infused was identical for all treatments across all volunteers, there 
was a tendency (p < 0.10) for the WL diet to have higher glucose concentrations (5%–8%) 60 to  
120 min into the dextrose infusion compared with the other three diets, with this effect more 
pronounced (p = 0.047) when expressed as changes in proportion to baseline glucose concentration. 
Over t e  a e  eri d,  la  a i   li  c  ce trati    were l wer  −37%, p < 0.001) for WL compared 
with the ot er 3 diet       li ae ia c  ti  ed t  re ai  l wer  −4 %, p < 0.001) during the first hour 
post-dextrose period for the WL diet and was still reduced, compared with the M diet, during the 
second hour post-dextr  e  −  %, p = 0.021). 
The greater C-peptide to insulin ratio for the WL versus M periods at fasting (Table 1) was 
maintained for the two diets both during and after the dextrose challenge (Table 3). When adjusted for 
the initial fasting value, however, the AUCi for C-peptide were not different between the WL and  
M diets for the 2 h either during or following the dextrose infusion (data not shown). 
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Table 3. Average 
1
 glucose (mM), insulin (pM) and C-peptide to insulin molar ratios for 
60 min intervals for the 2 h during and 2 h after dextrose infusion in 14 volunteers after an 
overnight fast following the dietary interventions 
2
. 
 
Time 
(min) 
M NSP RS WL SED 
P 
3 
Time 
P 
3 
Diet 
P 
3 
T × D 
Glucose 0–60 10.49 10.46 10.46 10.74 0.38 <0.001 0.450 0.209 
 60–120 13.67 14.04 13.84 14.74     
 120–180 8.34 8.56 8.51 8.90     
 180–240 4.81 4.63 4.67 4.79     
Insulin 0–60 294 a 287 a,b 294 a 199 b 45.6 <0.001 <0.001 0.001 
 60–120 689 a 352 a 634 a 437 b     
 120–180 572 a 601 a 544 a 353 b     
 180–240 214 a 185 a,b 161 a,b 107 b     
Cpep:Ins 0–60 8.61 a   11.37 b 2.596 0.028 <0.001 0.017 
 60–120 5.99   8.66     
 120–180 8.94   12.59     
 180-240 15.70 a   26.26 b     
1 Based on area under the curve (expressed per min) for each 60-min interval; 2 7 day maintenance (M), or 21 day high 
non-starch polysaccharide (NSP), high resistant starch (RS) or weight loss (WL) diets; 3 p-values from ANOVA with 
volunteer and nested within volunteer, period, time and their interaction as random effects, and with diet, time and their 
interaction as fixed effects; when main effects of diet or the time × diet interaction was significant post-hoc comparisons 
for diet were performed; SED values refer to main effects for diet; Values within rows with unlike superscripts are 
different at p < 0.05. 
3.5. Endogenous Glucose Production and Glucose ILR 
Based on the Simple model, estimated EGP approximately halved within 5 min of the start of 
dextrose infusion (data not shown) and was reduced to less than 10% (0.09 SEM 0.017) mmol/min) at 
30 min into the dextrose infusion and remained low for the remaining 90 min of challenge (Table 4). 
The decline in EGP was more rapid than the change in the TTR of plasma [6,6-
2
H2]glucose (Figure 3) 
because the latter included label return from the slow-equilibration pool. Nonetheless, diet did not 
affect the rate of EGP suppression (p = 0.60). 
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Table 4. Kinetic parameters showing effect of diet on glucose dynamics and insulin 
sensitivity, as assessed by the Simple model, for 60 min intervals for the 2 h during and  
2 h after dextrose infusion in 14 volunteers after an overnight fast following the  
dietary interventions 
1
. 
Variable
2
 
Time 
(min) 
M NSP RS WL SED 
P 
3
 
Time 
P 
3 
Diet 
P 
3 
T × D 
EGP 0–60 0.149 0.146 0.169 0.173 0.036 <0.001 0.601 0.966 
 60–120 0.002 0.006 0.013 0.015     
 120–180 0.076 0.083 0.101 0.128     
 180–240 0.428 0.373 0.389 0.418     
ILR 0–60 1.95 a 1.85 a,b 1.94 a 1.64 b 0.11 <0.001 0.830 0.012 
 60–120 3.74 a 3.74 a 3.73 a 3.72 a     
 120–180 3.07 a 3.23 a,b 3.20 a 3.42 b     
 180–240 1.40 a 1.38 a 1.38 a 1.54 a     
k01 0–60 0.0124
 a 0.0117 a 0.0122 a 0.0101 b 0.0011 <0.001 0.929 0.047 
 60–120 0.0184 a 0.0182 a 0.0182 a 0.0172 a     
 120–180 0.0261 a 0.0277 a 0.0268 a 0.0278 a     
 180–240 0.0194 a 0.0203 a 0.0207 a 0.0219 b     
ILR/Ins 0–60 8.83 a 9.33 a 8.67 a 13.50 a 2.834 <0.001 0.003 <0.001 
 60–120 0.045 a 0.049 a 0.046 a 0.075 a     
 120–180 9.17 a 9.34 a 9.84 a 17.84 b     
 180–240 11.84 a 13.50 a 13.00 a 27.84 b     
1 Seven day maintenance (M), or 21 day high non-starch polysaccharide (NSP), high resistant starch (RS) or weight loss 
(WL) diets; 2 EGP, endogenous glucose production (mmol/min); ILR, irreversible loss rate of glucose (mmol/min-1);  
k01, fractional rate of disappearance of glucose (/min); ILR/Ins, irreversible loss rate per unit insulin (μmol/L/pmol
 per 
min); 3 p-values from ANOVA with volunteer and nested within volunteer, period, time and their interaction as random 
effects, and with diet, time and their interaction as fixed effects. When diet or the time by diet (T × D) interaction was 
significant post-hoc comparisons for diet were performed. SED values refer to main effects for diet. Values within rows 
with unlike superscripts are different at p < 0.05. 
At the same times (5 and 30 min of dextrose infusion), observed glucose concentrations increased 
by 22% and 86%, respectively, while plasma insulin was raised by 93% and 347% with C-peptide still 
74% higher than baseline at 30 min. The rapidity of these changes, combined with the time intervals 
selected between samples, did not allow adequate resolution of the separate contributions of glucose 
and insulin to EGP suppression. The high plasma glucose and(or) insulin concentrations in the period 
after cessation of the dextrose infusion for some volunteers (Figure 3) continued to suppress EGP, as 
shown by the slow rate of decrease in the plasma [
13
C]glucose TTR. Indeed, 1.5 h after the dextrose 
infusion ceased, EGP was, on average, 410 (SEM 70) μmol/min, <50% of the basal rate. By this time 
plasma glucose concentrations were lower (−24%) than fasting glycaemia, while plasma insulin and  
C-peptide both remained elevated (+93% and +65%, respectively) compared with pre-dextrose 
infusion values. 
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Figure 3. Comparison of calculated endogenous glucose production (EGP) based on either 
the Simple model, that allows for return of label to primary pool, or assuming steady state, 
where no allowance for label return is included. Data from the M diet, but the other diets 
gave similar patterns (not shown). The difference in calculated EGP at time 0 is because 
the Simple model allowed for the slow decline in plasma glycaemia during the 2 h fasting 
prior to the dextrose challenge. Differences in the decline and recovery of EGP over time 
again reflect that the Simple model allows for the return of label to the plasma pool while 
the steady state approach does not.  
 
Based on the Simple model, the ILR of glucose (Table 4) was elevated markedly during  
60–120 min of dextrose infusion (3.73 mmol/min, SEM 0.19), dominated by exogenous glucose 
supply (3.47 mmol/min), and remained elevated during the first hour post-dextrose. The WL diet gave 
a lower ILR 0–60 min into the dextrose infusion, compared with the M (p = 0.004) and RS (p = 0.006) 
diets. This pattern was reversed for the first hour post-dextrose, with ILR remaining elevated on the 
WL diet compared with M and RS (p = 0.001 and p = 0.043 respectively). A similar pattern was 
observed for the fractional rate of removal, k01, which was lower for WL during the first h of dextrose 
infusion but remained higher for the last h of the post-glucose period. 
3.6. Insulin Sensitivity 
IS, an index of the responsiveness of peripheral tissue glucose disposal to the hormone, as 
determined by either the Formal or Simple models for the period during and post the dextrose infusion, 
improved during the period of weight loss compared with the other diets. For the Simple model, IS, 
assessed by glucose ILR divided by insulin concentration, improved by approximately two-fold on WL 
compared with the other three diets (p < 0.003; Table 4). This enhanced response resulted from  
a combination of increased ILR (Table 4) and lowered insulin (Table 3) with the WL diet. Similarly, 
with the Formal model, IS assessed as the response of glucose removal to the presence of insulin, sk, 
was increased for WL by 47%, 36% and 33% compared with M (p < 0.001), NSP and RS treatments 
(both p = 0.01), respectively (Table 5). Furthermore, IS remained elevated for the WL diet during the  
2 h after the dextrose infusion ceased (data not shown). For neither model was there any alteration of 
IS for the RS or NSP diets in comparison with the M diet (Tables 4 and 5). In addition, with the 
Formal model approach no parameter, other than sk, was altered by diet (Table 5).  
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Table 5. Estimated parameters 
1
 for the Formal model following the dietary interventions 
2
. 
Parameter M NSP RS WL SED P 3 Diet 
px (/min) 16.71 12.40 15.13 10.61 3.38 0.286 
sk (L/mU/min
2) 7.43 a 8.06 a 8.20 a 10.93 b 1.17 0.024 
pz (/min) 1.30 29.80 32.45 1.56 23.53 0.867 
g1 (L/mmol//min) 153 122 157 225 54.2 0.240 
1 px, reflects gradual dimunition of insulin effect with time; sk, enhanced glucose removal due to insulin;  
pz, reflects gradual dimunition of glucose effect with time; g1, reduced fractional glucose removal due to high 
glucose concentration; 2 Seven day maintenance (M), or 21 day high non-starch polysaccharide (NSP),  
high resistant starch (RS) or weight loss (WL) diets; 3 Based on ANOVA with volunteer as random effect and 
diet as fixed effect, 39 df. Post hoc t-test was performed when diet was significant (p < 0.05). SED values 
refer to main effect for diet. Values within rows with unlike superscripts are different at p < 0.05. 
Both models indicated there was an upper limit for glucose removal, particularly in the early phase 
of dextrose infusion when changes in glucose concentration exceed the response in insulin. Although 
the two models have different inherent advantages and disadvantages, both gave similar ILR and 
fractional removal rates, and showed the same effect of diet on the outcomes of interest (Tables 4 and 5). 
4. Discussion 
The challenge to health that accompanies obesity has led to a plethora of recommended approaches 
to reduce risks, including those associated with impaired IS. Among the proposed solutions is 
increased dietary fibre intake [44] or strategies that reduce body fat [8]. The current study addressed 
whether consumption of additional fibre, in the form of either NSP or RS, above that currently 
recommended for colonic health would improve metabolic health and IS in obese subjects who were 
weight-stable and how this would compare with improvements produced by a mild weight loss.  
An intervention of only three weeks was sufficient to increase IS following weight loss while 
improvements with RS or NSP, over a similar period, were marginal or non-existent. 
4.1. Protein Dynamics and Aminoacidaemia 
WL is well-known to improve metabolic health and IS [6–8] and so provides a good reference point 
for other dietary manipulations. In the current study a high-protein diet was used to support WL as this 
has proved effective in several laboratories and also ensures that lean mass is maintained [9–11]. This 
is important because amino acids provide an important precursor source for gluconeogenesis, 
particularly in the fasted state [22]. Indeed, when protein catabolism is increased so is the contribution 
of gluconeogenesis to glucose production and this is responsive to altered IS [20]. In practice, the RS 
diet had no effect on protein breakdown while both the NSP and WL diet caused a small decrease in 
the fasted condition. Whether this might also lead to reduced gluconeogenesis was not tested, although 
total EGP expressed per unit lean mass did decline. Alanine and glutamine are considered the most 
important non-essential amino acids that act as glucose precursors in humans [45] but only plasma 
concentrations of the former decreased after 3 weeks on the high protein WL diet. Interestingly, 
alanine also decreased with the RS diet, albeit to a lesser extent. Nonetheless, these indirect 
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observations would suggest that the contribution of amino acids to glucose synthesis in the fasted state 
is probably similar between the various diets examined in the current study.  
4.2. Endogenous Glucose Production 
Insulin regulates glycaemia by stimulation of glucose uptake by peripheral tissues and reduction of 
endogenous glucose production (EGP) by the liver. Either or both processes can be inhibited during IS. 
Hyper-insulinaemia in the portal vein suppresses both glycogenolysis and gluconeogenesis, the two 
major contributors to EGP, in non-diabetic subjects [46–48]. Elevated plasma glucose can also reduce 
EGP, mainly by suppression of glycogenolysis [35]. In the overnight fasted state, where neither insulin 
nor glucose are elevated, neither additional RS nor NSP impacted on EGP, which supports other 
observations [49,50]. In contrast, for the fasted state, the WL regime resulted in lowered EGP, 
although the 11% reduction was less than reported elsewhere [51]. Several factors may contribute to 
this decreased EGP. For example, the observed reduction in whole body protein breakdown may limit 
the amount of amino acid liberated from muscle and that contribute approximately 50% towards 
hepatic gluconeogenesis [52]. Alternatively, during WL mobilisation of body fat, production of ketone 
bodies may provide alternative sources of energy [53] and reduce the need for glucose.  
4.3. C-Peptide and Insulin 
High fibre intakes appear to exert little effect on overnight fasted plasma insulin [18,54], as also 
observed in the current study. Post-prandial responses in insulin and C-peptide secretion to altered 
dietary fibre intake have been varied, however. For example, no change was observed for the insulin 
AUC (both total and incremental) between a normal and high fibre diet (11 vs. 26.7 g/MCal), each 
supplied for 4 weeks [54]. In contrast, a 24 h prior supplementation with 60 g RS2 (as Novelose 260) 
reduced post-prandial excursions of both glucose and insulin [17], although C-peptide was unaltered. 
The same group reported that a 4 weeks supplementation with 30 g/day additional RS2  
(as Hi-maize 260) also reduced post-prandial insulin AUC [18]. There was also an increase in the  
C-peptide:insulin ratio, which supported earlier evidence that more insulin is removed by the liver with 
viscous fibre diets [55]. In contrast, the current study did not find an effect of the RS diet, when 
provided for 3 weeks as Novelose 330 (RS3), in response to infused dextrose. These differences 
between studies are difficult to reconcile, although both the form in which RS was supplied and the 
response conditions employed (test meal of mixed nutrients vs. intra-venous infused dextrose) may be 
critical. Furthermore, there were also no differences in the AUC for insulin for the NSP diet, which 
supports an earlier report with high fibre diets [54]. 
Although neither form of dietary fibre altered insulin responses, there were marked reductions in 
plasma insulin concentrations with the high protein WL diet, under both basal and glucose-stimulated 
conditions. Protein is a potent insulin secretagogue and acts synergistically when supplied with  
glucose [56]. Nonetheless, even after 5-week on a high protein, weight maintenance diet subjects with 
type 2 diabetes had similar overnight fasted plasma insulin concentrations compared with normal 
protein intake [4]. The lowered fasting insulin (and C-peptide) observed in the current study, therefore, 
may be due to either the hypo-caloric state and (or) the effect of weight loss. The latter may be more 
critical because in a number of studies where subjects lost weight and were then weight-stabilised for 
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1–2 weeks there were substantial declines in fasting insulin concentrations [8,57,58], although this has 
not always been observed [7]. Differences in fasting insulin and C-peptide between diets confound 
interpretation of pancreatic and hepatic responses to the glucose challenge. For example although there 
was lowered insulin AUCt and raised C-peptide:insulin ratio for WL compared with M, the 
incremental AUC for C-peptide was similar between the two diets. This may indicate that the response 
of the pancreas to the same glucose challenge was similar between the diets, even though the basal 
(fasting) parameters differed. Resolution of this issue requires use of more sophisticated models that 
define pancreatic responses under non-steady state conditions [40] and that allow for the different  
half-lives of C-peptide and insulin [59,60].  
4.4. Diet and Insulin Sensitivity 
Based on both the Formal and Simple models, peripheral IS altered in response to WL but not for 
either the RS or NSP diet. The improvement with WL ranged from 56% to 83%, dependent on the 
model selected, and was driven by lowered insulin concentrations rather than changes in either 
glycaemia or glucose disposal. These findings support a number of previous reports where responses to 
meals or glucose challenges have been investigated after weight loss [57,61] and with either 
maintained or improved glycaemia achieved at lowered insulin concentrations. Similarly, under 
conditions of hyper-insulinaemia the rate of glucose disposal is enhanced by weight loss in obese 
subjects [8,51,62]. Such improvements in glycaemic control by insulin can result from either increased 
disposal by peripheral (muscle) tissue [8,51] and (or) enhanced hepatic metabolism, whereby EGP is 
further suppressed while glucose uptake is maintained [51]. In the current study, suppression of EGP 
during WL exceeded 90% but this would only account for a decrease in hepatic output of 
approximately 1 mmol/min, insufficient to compensate for the rate of dextrose infusion (3.5 mmol/min) 
and, instead, increased glucose disposal occurred. 
Current UK recommendations for healthy eating include increased fibre intake by inclusion of fruit, 
vegetables and whole grains in the diet. Changes in dietary pattern may also affect other factors that 
influence IS, including altered diet glycaemic index (GI) [63], substitution of digestible carbohydrate 
by fermentable fibre [64] and inclusion of soluble fibre that lowers glucose absorption [14]. These 
various factors have complicated resolution of the direct effects of fibre components on metabolic 
health [65]. In practice, the amount of additional RS or NSP added to the current diets represented only 
7%–13% (w/w) of the total carbohydrate present with only limited impact on diet GI. Care was also 
taken to maintain a fixed proportion of calculated soluble:insoluble fibre for each menu day although, 
in practice, this was not fully achieved. Both the M and WL diets were considered to meet fibre needs 
for optimal colonic health [66] and the additional NSP or RS tested if improvements in metabolic 
health could be achieved through increased intake of either fibre source. This is particularly relevant in 
the case of RS as intake of this form of fibre is relatively low (5–10 g/day) in western diets and one 
form of supplemental RS2 has been shown to improve IS [18,67]. The lack of response in glucose 
metabolism to additional NSP agrees with earlier work where the dietary fibre was increased from  
11 to 27 g/Mcal intake [53], a greater differential than used in the current study (10.4, 13.5, 13.0 and 
14.5 g/Mcal for M, NSP, RS and WL diets respectively). The carefully controlled earlier study [54] 
used substitution with whole grain cereals, whole wheat bread, fruit and nuts to increase the fibre 
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intake but found no change fasting glucose or insulin, nor differences in AUCi for either glucose or 
insulin. In contrast, increased cereal fibre intake (from 14 g/day as control to either 26 or 43 g/day) for 
6 weeks did improve IS [50]. Interestingly, the improvement was similar for the two supplements and 
these increased total fibre intake from a control value of approximately 20 g/day to either 32 or  
50 g/day [50], calculated equivalent to 10, 13.5, 16 g/Mcal (from [50]). This compares with the current 
study where total fibre ingestion with the M diet was 32 g/day, raised to 42 and 44 g/day with the RS 
and NSP supplements respectively [23]. The reported findings [50,54], in combination with lack of 
change in IS in the current study, would suggest that increasing NSP above current recommendations 
for northern European countries [25] will not improve metabolic health, although there may be benefits 
on IS for those with habitual low fibre intake [50]. 
The situation is less clear in the case of RS. When soluble fibre was increased from 15 to 50 g/day 
by inclusion of additional fruit and vegetables in the diets of subjects with type 1 diabetes for  
a 4-week period there were significant reductions in mean daily blood glucose concentrations and 
glycosylated haemoglobin (HbA1c) [16]. These diet changes lowered the GI from 90% to 70% and this, 
rather than the inclusion of soluble fibre, may have been the main cause of the improvement. 
Nonetheless, other reports have suggested that either acute (24 h) [17] or chronic (4 week) [18] 
supplementation with 40 g/day RS in the form of high amylose maize (HAM-RS2) led to 
improvements in aspects of glycaemic control in healthy volunteers. The chronic study [18] showed an 
improved IS of 14%, assessed by the HIEC clamp procedure, but no change in HOMA. This was 
supported by later studies from the same group on subjects with metabolic syndrome and where IS 
improved by 19% [67], although this interpretation is slightly confounded by differences at baseline 
for the placebo and RS groups. In contrast, in further studies neither acute ingestion (24 g HAM-RS 
per meal) in healthy subjects [68] nor 4-week ingestion (40 g/day) in overweight subjects [69] showed 
improvement in either oral IS (by minimal model analysis) or HOMA parameters, Interestingly, lower 
doses of HAM-RS2 (15 and 30 g/day, each for 4 week) has recently been reported to increase IS 
(assessed by an insulin-modified IVGTT) in overweight and obese males but not their female 
counterparts [70].  
The above comparisons clearly demonstrate that even with the same (or similar) RS product  
a number of factors may influence whether IS can be improved [65]. The current study used retrograde 
RS-3 starch (manufactured by a cooking and cooling process) and was designed to test whether the 
increased fermentation to short chain fatty acids (especially propionate) in the caecum would enhance 
IS [17,65,71]. This form of RS was almost completely fermented (>96%) in all but two of the 
volunteers, with corresponding increases in the proportions of Eubacterium rectale, Ruminococcus 
bromii and Oscillibacter within the faecal bacteria [23]. Most of these changes were rapid, occurring 
within 3–4 days of the diet switch, and bacterial metabolite changes would be expected to occur over  
a similar period so that any direct effects exerted should be apparent after the 3 week on each diet. 
Despite this, the RS diet resulted in only a slight improvement in HOMA but with no change in IS as 
assessed by the IVGTT procedure adopted. Why differences in actions on IS exist between (or even 
within) forms of RS is not resolved. In some studies, the RS is provided as a supplement [18,69,70] 
and this may provoke changes in habitual intake (but insufficient to affect body weight). In contrast, 
the current volunteers were carefully managed with all food provided as prepared meals. As with any 
“live-out” study, however, it is impossible to eliminate consumption of additional foods and drinks. 
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Detailed bacterial changes associated with ingestion of RS2 (in the form of HAM) by humans have not 
been characterised and these may differ between RS2 and RS3 sources. Health benefits of RS 
consumption, other than changes related to IS, have been reported for the gastrointestinal tract, 
including crypt mitotic location, gene expression and DNA methylation [72].  
A further explanation for the apparent inconsistency in response to RS may relate to the methods 
used to determine IS. The initial studies with HAM-RS2 [18] adopted the HIEC approach and reported 
improvements of 14%. Use of Minimal Models, either in conventional form or as modified here, either 
found no response [69] or numerical improvements (RS +17% and NSP +15%) that did not reach 
statistical significance (current study). The intra-venous based Minimal Models involve insulin only 
released from the pancreas whereas the HIEC procedure involves a fixed exogenous supply plus 
pancreatic secretion. The additional biological variance associated with Minimal Models, although 
more closely simulating the natural state, may increase the difficulty in detecting small differences. 
Interestingly, the recently study with HAM-RS2 and use of an insulin-stimulated Minimal Model did 
observe significant responses but here the improvement in IS approached 50%. Nonetheless, within the 
current study any improvement with either NSP or RS3 was far less than the 37%–53% achieved by  
a modest 3-week weight loss. 
5. Conclusions 
The failure of advice from the medical profession, scientists and governments for people to lose 
weight has forced consideration of whether people can be fat but healthy (metabolically healthy but 
obese, MHO). Although a proportion of the population appears to be naturally MHO [73], which may 
be associated with factors such as distribution of fat mass [74] and inflammatory status [75], the 
question remains are there simple life-style interventions than can improve metabolic health in the 
majority of the obese population? The current study suggests that, in the short term, this is not 
achieved by moderate increases fibre intake, either in RS or NSP form, above that currently 
recommended. There may be effects of such dietary interventions but these appear small compared 
with the improvements achieved by only a very modest weight loss. Of course, there may be additional 
beneficial effects on gut health, especially in the colon [15,72,76]. The careful nutritional control 
exerted in the current study was of only limited duration and other benefits may emerge from longer 
studies, as observed with low GI diets [12]. Furthermore, dietary fibre may alleviate the potential 
reduction in IS induced by certain nutrients, including protein [50]. Nonetheless, longer term weight 
loss also produces substantial benefits in terms of metabolic health [61] and so the route of reduced 
body mass should still be the main target of lifestyle intervention.  
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